Showing results (1981-1990 of 2,116) with videos related to

Sort By:
Pageof 212
Nature Genetics|July 1, 2014
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1Laura Fachal, Antonio Gómez-Caamaño, Gillian C Barnett, et al.
Journal of the American College of Cardiology|August 27, 2025
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM TrialMilind Y Desai, Iacopo Olivotto, Theodore Abraham, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2004
Insights into the evolution of Yersinia pestis through whole-genome comparison with Yersinia pseudotuberculosisP S G Chain, E Carniel, F W Larimer, et al.
European Journal of Heart Failure|June 19, 2019
Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel reportPerry M Elliott, Aris Anastasakis, Angeliki Asimaki, et al.
Journal of the American College of Cardiology|January 28, 2012
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort studyIngrid A W van Rijsingen, Eloisa Arbustini, Perry M Elliott, et al.
European Journal of Preventive Cardiology|November 1, 2024
Arrhythmic risk stratification in patients with left ventricular ring-like scarVanda Parisi, Maddalena Graziosi, Luis R Lopes, et al.
JCSM Communications|January 22, 2026
Automated Segmentation of Forearm Muscles: Clinical Associations With Hand Function, Muscle Volume and Intramuscular FatJoel Fundaun, Valeria Oliva, Sandrine Bédard, et al.
Viruses|January 8, 2025
Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 VaccinationNicholas Bbosa, Ronald Kiiza, Alfred Ssekagiri, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Immunotherapy Advances|August 4, 2023
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trialAndrew Abaasa, Moses Egesa, Emmanuella Driciru, et al.
Pageof 212